Here, we used PPARγ agonist Rosiglitazone or PPARγ antagonist T0070907 to intervene the PPARγ pathway and to investigate whether pharmacological activation or inhibition of PPARγ would affect the cancer cell survival. The gene discussed is PPARG; the disease is cancer.